Inavolisib and its Impurities

Inavolisib, development code GDC-0077, is an oral targeted therapy drug classified as a PI3K inhibitor, specifically targeting the PI3K-alpha isoform. It is being developed by Genentech or Roche for the treatment of certain cancers. Reference standards of Inavolisib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.